AR072039A1 - Anticuerpos contra el virus de la hepatitis c - Google Patents

Anticuerpos contra el virus de la hepatitis c

Info

Publication number
AR072039A1
AR072039A1 ARP080105506A ARP080105506A AR072039A1 AR 072039 A1 AR072039 A1 AR 072039A1 AR P080105506 A ARP080105506 A AR P080105506A AR P080105506 A ARP080105506 A AR P080105506A AR 072039 A1 AR072039 A1 AR 072039A1
Authority
AR
Argentina
Prior art keywords
seq
humanized antibody
antigen binding
binding fragment
hepatitis
Prior art date
Application number
ARP080105506A
Other languages
English (en)
Spanish (es)
Inventor
David J Matthews
David G Williams
Arvind Patel
Original Assignee
Medical Res Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council Technology filed Critical Medical Res Council Technology
Publication of AR072039A1 publication Critical patent/AR072039A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
ARP080105506A 2007-12-17 2008-12-18 Anticuerpos contra el virus de la hepatitis c AR072039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US606607P 2007-12-17 2007-12-17

Publications (1)

Publication Number Publication Date
AR072039A1 true AR072039A1 (es) 2010-08-04

Family

ID=40801628

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105506A AR072039A1 (es) 2007-12-17 2008-12-18 Anticuerpos contra el virus de la hepatitis c

Country Status (18)

Country Link
US (1) US9193781B2 (https=)
EP (1) EP2231704B1 (https=)
JP (1) JP5763344B2 (https=)
KR (1) KR20100102163A (https=)
CN (1) CN101939334B (https=)
AR (1) AR072039A1 (https=)
AU (1) AU2008341542B2 (https=)
BR (1) BRPI0821252A2 (https=)
CA (1) CA2708740C (https=)
CL (1) CL2008003784A1 (https=)
IL (1) IL205795A0 (https=)
MX (1) MX2010006767A (https=)
NZ (1) NZ585622A (https=)
PE (1) PE20091109A1 (https=)
RU (1) RU2462475C2 (https=)
TW (1) TW200940090A (https=)
WO (1) WO2009081285A2 (https=)
ZA (1) ZA201003509B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103931605B (zh) 2004-10-07 2015-11-18 特兰斯迈迪茨公司 用于活体外器官护理的系统和方法
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
US9457179B2 (en) 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US8420380B2 (en) 2008-01-31 2013-04-16 Transmedics, Inc. Systems and methods for ex vivo lung care
KR20110101212A (ko) * 2008-12-17 2011-09-15 제넨테크, 인크. Ｃ형 간염 바이러스 조합 요법
US20130011823A1 (en) 2011-04-14 2013-01-10 Hassanein Waleed H Organ care solution for ex-vivo machine perfusion of donor lungs
EP2705150B1 (en) * 2011-05-02 2020-07-29 The Johns Hopkins University A synthetic hepatitis c genome and methods of making and use
WO2013033319A2 (en) * 2011-08-30 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University A cluster of neutralizing antibodies to hepatitis c virus
JP6061944B2 (ja) * 2011-12-09 2017-01-18 アプライド マテリアルズ インコーポレイテッドＡｐｐｌｉｅｄ Ｍａｔｅｒｉａｌｓ，Ｉｎｃｏｒｐｏｒａｔｅｄ 加熱管を冷却する熱交換器、蒸発器の加熱管、加熱管を備える蒸発器および蒸発器の加熱管を冷却する方法
ITFI20120122A1 (it) * 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
CN102928595A (zh) * 2012-10-12 2013-02-13 武汉康苑生物医药科技有限公司 丙型肝炎病毒抗原抗体时间分辨免疫荧光分析法联合检测及检测试剂盒
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
BR112016006122B1 (pt) 2013-09-19 2023-11-14 Novavax, Inc COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV)
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
JP2017518301A (ja) 2014-06-02 2017-07-06 トランスメディクス， インク．Ｔｒａｎｓｍｅｄｉｃｓ， Ｉｎｃ． ｅｘ−ｖｉｖｏでの臓器管理システム
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CA3155169A1 (en) 2014-12-12 2016-06-16 Tevosol, Inc. Apparatus and method for organ perfusion
CA2997267A1 (en) 2015-09-09 2017-03-16 Transmedics, Inc. Aortic cannula for ex vivo organ care system
CN105219780B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用
CN105177017B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r4-85及其应用
CN109641955B (zh) * 2016-03-22 2022-07-08 国家医疗保健研究所 人源化抗claudin-1抗体及其用途
ES2968062T3 (es) 2016-05-30 2024-05-07 Transmedics Inc Aparato y método de ventilación pulmonar ex vivo con presión exterior variable
AU2017382883B2 (en) 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405053B (de) * 1991-06-10 1999-05-25 Lucky Ltd Hepatitis-c-diagnosemittel und -impfstoffe
ITPN960013A1 (it) * 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
EP1355947A2 (en) * 2000-12-01 2003-10-29 The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
ITRM20020049A1 (it) * 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
CA2601400A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections

Also Published As

Publication number Publication date
CA2708740C (en) 2017-07-18
MX2010006767A (es) 2010-10-05
WO2009081285A3 (en) 2010-08-26
WO2009081285A2 (en) 2009-07-02
JP5763344B2 (ja) 2015-08-12
TW200940090A (en) 2009-10-01
CA2708740A1 (en) 2009-07-02
JP2011505867A (ja) 2011-03-03
IL205795A0 (en) 2010-11-30
NZ585622A (en) 2012-10-26
BRPI0821252A2 (pt) 2015-06-16
AU2008341542B2 (en) 2014-12-04
RU2462475C2 (ru) 2012-09-27
HK1144440A1 (en) 2011-02-18
US20110002926A1 (en) 2011-01-06
CL2008003784A1 (es) 2009-08-14
EP2231704A2 (en) 2010-09-29
ZA201003509B (en) 2011-12-28
PE20091109A1 (es) 2009-08-12
RU2010129429A (ru) 2012-01-27
US9193781B2 (en) 2015-11-24
AU2008341542A1 (en) 2009-07-02
CN101939334A (zh) 2011-01-05
CN101939334B (zh) 2015-01-14
KR20100102163A (ko) 2010-09-20
EP2231704B1 (en) 2015-08-12

Similar Documents

Publication Publication Date Title
AR072039A1 (es) Anticuerpos contra el virus de la hepatitis c
CA2712605C (en) Monoclonal antibodies for ebola and marburg viruses
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
AR085624A2 (es) Anticuerpos de p-caderina
AR068767A1 (es) Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
JP6957355B2 (ja) 血清型交差反応性デング熱中和抗体及びその使用
AR045056A1 (es) Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
AR069062A1 (es) Anticuerpo anti-hepcidina
NZ578844A (en) Human cytomegalovirus neutralising antibodies and use thereof
WO2008031133A3 (en) Borrelia antigens
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
BR112012007860A2 (pt) "anticorpos siglec 15 no tratamento de doença relativa a perda óssea"
RU2015150149A (ru) Составы на основе биспецифических антител к il-4/il-13
WO2007038637A3 (en) Human monoclonal antibodies to cd70
CO6361947A2 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamina
CN104447986A (zh) 一种中东呼吸综合征冠状病毒中和抗体及其制备方法
PE20240086A1 (es) Anticuerpos anti-cd122 y usos de estos
AR125488A1 (es) Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas
AR127271A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
CN113527473A (zh) 一种全人源单克隆抗体及其应用
DE602005027399D1 (de) Für humane matriptase spezifische bindungsproteine
WO2020186687A1 (zh) 一种特异性结合四种血清型登革病毒的人源抗体

Legal Events

Date Code Title Description
FA Abandonment or withdrawal